King Fraya, Klonoff David C, Ahn David, Adi Saleh, Berg Erika Gebel, Bian Jiang, Chen Kong, Drincic Andjela, Heyl Michael, Magee Michelle, Mulvaney Shelagh, Pavlovic Yarmela, Prahalad Priya, Ryan Michael, Sabharwal Ashutosh, Shah Shahid, Spanakis Elias, Thompson Bradley Merrill, Thompson Michael, Wang Jing
1 Mills-Peninsula Medical Center, San Mateo, CA, USA.
2 Mary & Dick Allen Diabetes Center at Hoag, Newport Beach, CA, USA.
J Diabetes Sci Technol. 2019 Jan;13(1):128-139. doi: 10.1177/1932296818810436. Epub 2018 Nov 5.
Diabetes Technology Society (DTS) convened a meeting about the US Food and Drug Administration (FDA) Digital Health Software Precertification Program on August 28, 2018. Forty-eight attendees participated from clinical and academic endocrinology (both adult and pediatric), nursing, behavioral health, engineering, and law, as well as representatives of FDA, National Institutes of Health (NIH), National Telecommunications and Information Administration (NTIA), and industry. The meeting was intended to provide ideas to FDA about their plan to launch a Digital Health Software Precertification Program. Attendees discussed the four components of the plan: (1) excellence appraisal and certification, (2) review pathway determination, (3) streamlined premarket review process, and (4) real-world performance. The format included (1) introductory remarks, (2) a program overview presentation from FDA, (3) roundtable working sessions focused on each of the Software Precertification Program's four components, (4) presentations reflecting the discussions, (5) questions to and answers from FDA, and (6) concluding remarks. The meeting provided useful information to the diabetes technology community and thoughtful feedback to FDA.
糖尿病技术协会(DTS)于2018年8月28日召开了一次关于美国食品药品监督管理局(FDA)数字健康软件预认证计划的会议。来自临床和学术内分泌学(成人和儿科)、护理、行为健康、工程和法律领域的48名与会者,以及FDA、美国国立卫生研究院(NIH)、国家电信和信息管理局(NTIA)和行业代表参加了会议。此次会议旨在就FDA推出数字健康软件预认证计划的方案提供意见。与会者讨论了该方案的四个组成部分:(1)卓越评估与认证;(2)审查途径确定;(3)简化上市前审查流程;(4)实际性能。会议形式包括:(1)开场发言;(2)FDA的方案概述介绍;(3)围绕软件预认证计划四个组成部分展开的圆桌工作会议;(4)反映讨论情况的报告;(5)向FDA提问及FDA作答;(6)总结发言。本次会议为糖尿病技术领域提供了有用信息,并向FDA提供了深思熟虑的反馈。